| Business Summary | | OXiGENE,
Inc.
is
an
international
biopharmaceutical
development-stage
company
engaged
principally
in
research
into,
and
the
development
of
products
for
use
in,
the
treatment
of
cancer.
OXiGENE
has,
in
various
stages
of
clinical
development,
therapeutic
product
candidates
that
derive
from
two
principal
technology
platforms,
the
Combretastatin
Platform
and
the
Benzamide
Platform.
The
Company's
primary
technology
platform
is
based
on
Combretastatin.
Combretastatin
is
a
family
of
proprietary
small-molecule,
anti-tumor
vascular
targeting
agents
that
destroy
the
existing
blood
vessels
within,
and
to
some
extent
the
blood
vessels
leading
to,
a
tumor,
thereby
stopping
the
growth
of
the
tumor,
shrinking
it
and
preventing
it
from
metastasizing.
The
benzamide
platform
was
originally
developed
by
the
Company
around
inhibition
of
DNA
repair
processes.
The
third-generation
benzamide
is
Declopramide
(formerly
Oxi-104),
which
makes
tumor
cells
more
susceptible
to
radiation
damage
and/or
chemotherapy. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OXiGENE,
Inc.
is
a
development
stage
biopharmaceutical
company
engaged
principally
in
the
research
into
and
the
development
of
products
for
use
in
the
treatment
of
cancer.
For
the
six
months
ended
6/30/01,
total
revenues
decreased
16%
to
$1.8
million.
Net
loss
increased
36%
to
$5.9
million.
Results
reflect
lower
interest
income,
the
absence
of
unrealized
investment
gains
and
increased
general
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Bjorn Nordenvall, M.D., Ph.D., 49 Chairman,
Pres, CEO | $300K | Frederick Driscoll, 50 Pres
of Operations and Fin. | 42K | David Chaplin, M.D., 45 COO
and Head of R&D and Chief Scientific Officer | 150K | David Sherris, M.D., Ph.D., 48 VP-R&D | 264K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|